NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care

描述（由申请人提供）：本申请的总体目标是法伯/合作伙伴癌症护理（DF/PCC）作为NCTN的主要学术参与站点，并成为NCTN活动的主要贡献者。DF/PCC是一家合资企业，专注于开展临床试验和临床研究者培训，横跨三个哈佛附属机构：丹娜-法伯癌症研究所、布里格姆妇女医院和马萨诸塞州总医院。它们都是癌症临床研究领域的国家领导者，并通过一个建立良好的统一临床试验项目团结工作。具体目标是：提供领导者开发和开展临床试验，并通过大量，稳健的累积支持NCTN。虽然DF/PCC将主要隶属于联盟网络集团，但学院将继续与各种网络集团建立牢固的历史关系。通过多种PD/PI模型、跨学科的教师队伍和强大的操作基础设施，DF/PCC将为试验开发试验提供高级科学投入；确定要进行的新试验

DESCRIPTION (provided by applicant): The overall goal of this application is for Farber/Partners Cancer Care (DF/PCC) to serve as a Lead Academic Participating Site in NCTN and become a leading contributor to NCTN activities. DF/PCC is a joint venture focused on conducting clinical trials and clinical investigator training by across three Harvard- affiliate institutions: Dana-Farber Cancer Institute, Brigham & Women's Hospital, and Massachusetts General Hospital. All are national leaders in cancer clinical research and work cohesively through a well- established unified clinical trials program. Specific aims are: provide leaders to develop and conduct clinical trials, and support NCTN through substantial, robust accrual. While DF/PCC will have as its primary affiliation the Alliance Network Group, faculties will continue their strong historical relationships with a variety of Network Groups. Through a multiple PD/PI model, an engaged interdisciplinary faculty, and a strong operational infrastructure, DF/PCC will provide senior scientific input to trial development trials; identify novel trials to be brought to NCTN; prioritize NCTN trials within our clinical trials portfolio; assure timely activation; provid training and mentoring; distribute funding fairly; and ensure adherence at participating sites. DF/PCC will impact NCTN, which will define new standards of care for adult patients with cancer through 1) scientific leadership in the Steering Committees; 2) participation in CIRB; 3) executive and committee leadership and membership; 4) executive and committee leadership, as well as committee membership; 5) serving as affiliated PIs; 6) leadership in accrual; and 7) training a new generation to participate in the national clinical trials network enterprise.